Generic diabetes combo drug put to the test in healthy volunteers

NCT ID NCT07633015

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study checked whether a generic version of the diabetes drug empagliflozin/metformin is absorbed into the body the same way as the brand-name drug Synjardy. 42 healthy adults took a single dose of each tablet under fed conditions. The goal was to see if the two versions are bioequivalent, meaning they work equally well.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Empagliflozin and Metformin combination tablet

What this could lead to

If successful, this could confirm that the generic version is equivalent to the brand-name drug, potentially offering a lower-cost option for patients.

What could go wrong

This is a small, early-stage bioequivalence study in healthy volunteers, not patients. Results may not predict real-world effectiveness or safety in people with diabetes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIOEQUIVALENCE STUDY IN HEALTHY SUBJECTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Axis Clinicals Latina, S.A. de C.V.

    Mexico City, Mexico City, 07870, Mexico